• Info
  • Significant Ownership

Significant Ownership of AbbVie Biotechnology Ltd

Signature - Title
/s/ Arthur C. Price - Arthur C. Price/Director
Location
Hamilton
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by AbbVie Biotechnology Ltd.

Follow Filing Activity

Follow AbbVie Biotechnology Ltd and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.

Significant Ownership of AbbVie Biotechnology Ltd

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CARM Carisma Therapeutics Inc. Common Stock, $0.001 par value 4.4% $408,292 1,855,871 AbbVie Biotechnology Ltd. 31 Mar 2025

Schedules 13D/G Reported by AbbVie Biotechnology Ltd:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.